VintaBio announced it has filed provisional patents with the U.S. Patent and Trademark Office for a new approach to manufacturing biotherapeutics using adherent culturing methods in small-scale ...

Nexture Bio has acquired Matrix F.T. Nexture Bio plans to make its expanded portfolio of high-performing adherent cell culture products available to a global range of customers and partners, including ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Univercells Technologies agreed to collaborate with Repligen to integrate real-time monitoring capabilities and enhance the development and manufacturing of viral vectors and vaccines. Repligen’s ...